PMID- 9935203
OWN - NLM
STAT- MEDLINE
DCOM- 19990216
LR  - 20220321
IS  - 0020-7136 (Print)
IS  - 0020-7136 (Linking)
VI  - 80
IP  - 2
DP  - 1999 Jan 18
TI  - Tumor regressions observed in patients with metastatic melanoma treated with an 
      antigenic peptide encoded by gene MAGE-3 and presented by HLA-A1.
PG  - 219-30
AB  - Thirty-nine tumor-bearing patients with metastatic melanoma were treated with 3 
      subcutaneous injections of the MAGE-3.A1 peptide at monthly intervals. No 
      significant toxicity was observed. Of the 25 patients who received the complete 
      treatment, 7 displayed significant tumor regressions. All but one of these 
      regressions involved cutaneous metastases. Three regressions were complete and 2 
      of these led to a disease-free state, which persisted for more than 2 years after 
      the beginning of treatment. No evidence for a cytolytic T lymphocyte (CTL) 
      response was found in the blood of the 4 patients who were analyzed, including 2 
      who displayed complete tumor regression. Our results suggest that injection of 
      the MAGE-3.A1 peptide induced tumor regression in a significant number of the 
      patients, even though no massive CTL response was produced.
FAU - Marchand, M
AU  - Marchand M
AD  - Ludwig Institute for Cancer Research, Brussels Branch, and Universite Catholique 
      de Louvain, Belgium. marchand@licr.ucl.ac.be
FAU - van Baren, N
AU  - van Baren N
FAU - Weynants, P
AU  - Weynants P
FAU - Brichard, V
AU  - Brichard V
FAU - Dreno, B
AU  - Dreno B
FAU - Tessier, M H
AU  - Tessier MH
FAU - Rankin, E
AU  - Rankin E
FAU - Parmiani, G
AU  - Parmiani G
FAU - Arienti, F
AU  - Arienti F
FAU - Humblet, Y
AU  - Humblet Y
FAU - Bourlond, A
AU  - Bourlond A
FAU - Vanwijck, R
AU  - Vanwijck R
FAU - Lienard, D
AU  - Lienard D
FAU - Beauduin, M
AU  - Beauduin M
FAU - Dietrich, P Y
AU  - Dietrich PY
FAU - Russo, V
AU  - Russo V
FAU - Kerger, J
AU  - Kerger J
FAU - Masucci, G
AU  - Masucci G
FAU - Jager, E
AU  - Jager E
FAU - De Greve, J
AU  - De Greve J
FAU - Atzpodien, J
AU  - Atzpodien J
FAU - Brasseur, F
AU  - Brasseur F
FAU - Coulie, P G
AU  - Coulie PG
FAU - van der Bruggen, P
AU  - van der Bruggen P
FAU - Boon, T
AU  - Boon T
LA  - eng
PT  - Clinical Trial
PT  - Controlled Clinical Trial
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Int J Cancer
JT  - International journal of cancer
JID - 0042124
RN  - 0 (Antigens, Neoplasm)
RN  - 0 (HLA-A1 Antigen)
RN  - 0 (MAGEA3 protein, human)
RN  - 0 (Neoplasm Proteins)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Antigen Presentation
MH  - Antigens, Neoplasm/adverse effects/genetics/*therapeutic use
MH  - Disease Progression
MH  - Female
MH  - Genetic Code
MH  - HLA-A1 Antigen/*immunology
MH  - Humans
MH  - *Immunotherapy
MH  - Male
MH  - Melanoma/secondary/*therapy
MH  - Middle Aged
MH  - Neoplasm Proteins/adverse effects/genetics/*therapeutic use
MH  - Remission Induction/*methods
EDAT- 1999/02/06 03:14
MHDA- 2000/06/20 09:00
CRDT- 1999/02/06 03:14
PHST- 1999/02/06 03:14 [pubmed]
PHST- 2000/06/20 09:00 [medline]
PHST- 1999/02/06 03:14 [entrez]
AID - 10.1002/(SICI)1097-0215(19990118)80:2<219::AID-IJC10>3.0.CO;2-S [pii]
AID - 10.1002/(sici)1097-0215(19990118)80:2<219::aid-ijc10>3.0.co;2-s [doi]
PST - ppublish
SO  - Int J Cancer. 1999 Jan 18;80(2):219-30. doi: 
      10.1002/(sici)1097-0215(19990118)80:2<219::aid-ijc10>3.0.co;2-s.